DFFN - Diffusion Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8600
-0.1403 (-4.68%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.0003
Open3.4400
Bid2.85 x 800
Ask3.00 x 800
Day's Range2.6500 - 3.7400
52 Week Range0.1900 - 3.7400
Volume723,267
Avg. Volume241,366
Market Cap144.84M
Beta (3Y Monthly)-2.02
PE Ratio (TTM)N/A
EPS (TTM)-0.58
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-15, effective for trading purposes prior to the opening of the market on December 14, 2018. The Company’s ticker symbol, DFFN, will remain unchanged. The new CUSIP number for Diffusion’s post-reverse split common stock will be 253748 305.

  • Zacks Small Cap Research5 days ago

    DFFN: Phase 2 Clinical Trial of TSC in Acute Stroke to Commence in 2019…

    In early 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” to be presented at the International Stroke Conference. The abstract discussed the design and rationale for a planned Phase 2 study of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation, in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. The Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T) will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke.

  • GlobeNewswirelast month

    Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that Chief Scientific Officer Dr. John L. Gainer will join leading clinicians and researchers from around the world in presenting a poster at the 2018 Annual Meeting of the Society for NeuroOncology (SNO) on Saturday, November 17, 2018 from 5:00-7:00pm EST. SNO’s 23rd Annual Scientific Meeting and Education Day will be held from Thursday, November 15, 8:00am through Sunday, November 18, 1:00pm at the Marriott Hotel, New Orleans, Louisiana.

  • GlobeNewswirelast month

    Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Officer CHARLOTTESVILLE, Va., Nov. 14,.

  • GlobeNewswire2 months ago

    Diffusion Pharmaceuticals Chief Financial Officer William “Bill” Hornung to Present at 2018 BIO Investor Forum

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that Chief Financial Officer William “Bill” Hornung will join leaders from the world’s top pharmaceutical, life sciences, and technology companies to present at the 2018 BIO Investor Forum on Thursday, October 18, 2018 at 1:15PM EST/10:15AM PST. Designed to “explore investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies,” the BIO Investor Forum brings industry innovators and leading investors together for an opportunity to learn about the latest industry trends and news.

  • GlobeNewswire3 months ago

    Diffusion Names William (“Bill”) Hornung Chief Financial Officer

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that it has appointed William (“Bill”) Hornung to the position of Chief Financial Officer. Mr. Hornung previously served as Chief Business Officer at the Company, in which capacity he had overseen the company’s business development and investor relations strategies.

  • Zacks Small Cap Research4 months ago

    DFFN: Enrollment Continues in Phase 3 Trial of TSC in GBM

    Early in 2018, Diffusion (DFFN) announced that the first patient has been dosed in the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial. The trial is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis. Patients will be randomized 1:1 to receive TSC along with standard of care radiation and chemotherapy (temozolimide) or standard of care alone.

  • Zacks Small Cap Research7 months ago

    DFFN: Preparing for Phase 2 Clinical Trial of TSC in Acute Stroke

    In early 2018, Diffusion (DFFN) announced the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” to be presented at the International Stroke Conference. The abstract discussed the design and rationale for a planned Phase 2 study of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation, in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. The Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T) will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke.

  • Zacks Small Cap Research8 months ago

    DFFN: Enrollment in Phase 3 GBM Trial Continuing

    On April 3, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for 2017 and provided a business update. The primary outcome of the study is overall survival at two years between the two groups.

  • ACCESSWIRE8 months ago

    Diffusion Pharmaceuticals to Present at The MicroCap Conference

    NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (''Diffusion'' or ''the Company''), a clinical-stage biotechnology company focused on extending the life expectancy ...

  • Zacks Small Cap Research10 months ago

    DFFN: Phase 3 GBM Trial Underway; Planning for Phase 2 Trial in Stroke

    On January 29, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced that the first patient has been dosed in the Phase 3 clinical trial of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation and potentially improve outcomes associated with radiation and chemotherapy cancer treatments. The trial has been named INTACT (INvestigating Tsc Against Cancerous Tumors) and is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis.

  • Diffusion Pharmaceuticals Inc (DFFN): Shoring up the Balance Sheet by Selling Stock Comes with a Price
    SmarterAnalyst11 months ago

    Diffusion Pharmaceuticals Inc (DFFN): Shoring up the Balance Sheet by Selling Stock Comes with a Price

    Shares of clinical-stage biotechnology company Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) are crashing – down nearly 40% as of this writing. Diffusion announced this morning that it will be selling at least 15 million shares of its own stock to raise cash for research and development of the company's lead product candidate, transcrocetinate sodium, including clinical trial activities, and for general corporate purposes. Each share of common stock is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.80 per share and accompanying common warrant. The common warrants will be exercisable at an exercise price of $0.80 per share and will expire five years from the date of issuance.

  • ACCESSWIRE11 months ago

    Today’s Research Reports on Stocks to Watch: Diffusion Pharmaceuticals and Pain Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 10, 2018 / Diffusion Pharmaceuticals and Pain Therapeutics were two biotech stocks scorching on Tuesday. Shares of Pain Therapeutics even hit a new high after announcing ...